Safety Assessment of Food Additives: Case Example With Myrcene, a Synthetic Flavoring Agent

被引:1
作者
Mog, Steven R. [1 ]
Zang, Yu Janet [1 ]
机构
[1] US FDA, Ctr Food Safety & Appl Nutr, Off Food Addit Safety, 5001 Campus Dr, College Pk, MD 20740 USA
关键词
food additive; toxicology; pathology; regulatory review; myrcene; HYALINE DROPLET NEPHROPATHY;
D O I
10.1177/0192623319879634
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
In the United States, the Food and Drug Administration (FDA) regulates the safe use of food ingredients, including food additives. Food additives are subject to FDA premarket review and approval, a process conducted by FDA scientists to evaluate the additive's safety for the intended conditions of use. Typically, an acceptable daily intake level is established by toxicologists based on the highest no observable adverse effect level for the most sensitive noncancer toxicity end point determined from a pivotal nonclinical study with application of an appropriate safety factor. Utilizing other information, including the additive's use and exposure levels, a safety determination (reasonable certainty of no harm) is made. During ongoing safety assessments, pathologists are often consulted by toxicologists for case-specific reasons, which may include verifying that an observed pathological effect is treatment related and adverse, confirming the determination of the pivotal study, endorsing a mode of action, or evaluating the human relevance of a toxicological effect found in experimental animals. Last year, the FDA took regulatory action to no longer allow the use of the food additive myrcene, a synthetic flavoring agent, based on results from National Toxicology Program carcinogenicity studies. The cancer and noncancer end points from the rat studies are discussed.
引用
收藏
页码:1035 / 1037
页数:3
相关论文
共 8 条
[1]  
[Anonymous], 2018, FED REG, V83
[2]  
[Anonymous], 2010, OECD GUID TEST CHEM
[3]   Complex Histopathologic Response in Rat Kidney to Oral β-myrcene: An Unusual Dose-related Nephrosis and Low-dose Alpha2u-Globulin Nephropathy [J].
Cesta, Mark F. ;
Hard, Gordon C. ;
Boyce, John T. ;
Ryan, Michael J. ;
Chan, Po C. ;
Sills, Robert C. .
TOXICOLOGIC PATHOLOGY, 2013, 41 (08) :1068-1077
[4]   HAZARD EVALUATION OF CHEMICALS THAT CAUSE ACCUMULATION OF ALPHA-2U-GLOBULIN, HYALINE DROPLET NEPHROPATHY, AND TUBULE NEOPLASIA IN THE KIDNEYS OF MALE-RATS [J].
HARD, GC ;
RODGERS, IS ;
BAETCKE, KP ;
RICHARDS, WL ;
MCGAUGHY, RE ;
VALCOVIC, LR .
ENVIRONMENTAL HEALTH PERSPECTIVES, 1993, 99 :313-349
[5]   Association of Advanced Chronic Progressive Nephropathy (CPN) with Renal Tubule Tumors and Precursor Hyperplasia in Control F344 Rats from Two-Year Carcinogenicity Studies [J].
Hard, Gordon C. ;
Betz, Laura J. ;
Seely, John Curtis .
TOXICOLOGIC PATHOLOGY, 2012, 40 (03) :473-481
[6]   Some Aids to Histological Recognition of Hyaline Droplet Nephropathy in Ninety-Day Toxicity Studies [J].
Hard, Gordon C. .
TOXICOLOGIC PATHOLOGY, 2008, 36 (07) :1014-1017
[7]  
Pressman P., 2017, FOOD ADDITIVE SAFETY, DOI [10.1177/2397847317723572, DOI 10.1177/2397847317723572]
[8]   FDA'S food ingredient approval process Safety assurance based on scientific assessment [J].
Rulis, Alan M. ;
Levitt, Joseph A. .
REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2009, 53 (01) :20-31